Stocks of Nektar Therapeutics (NASDAQ:NKTR) traded higher last session on Wall Street, up 1.92% to $29.68.
NKTR stock price is now 165.22% away from the 50-day moving average and 108.00% away from the 200-day moving average. The market capitalization of the company currently stands at $368.24M.
With the price target enhanced from $6.50 to $120, H.C. Wainwright maintained Buy rating for Nektar Therapeutics (NASDAQ: NKTR). On June 24, 2025, BTIG Research reiterated its ‘Buy’ rating on the stock by increasing its target price from $60 to quote $100, while ‘Jefferies’ rates the stock as ‘Buy’
In other news, Zalevsky Jonathan, Chief R&D Officer sold 10,712 shares of the company’s stock on May 19 ’25. The stock was sold for $7,177 at an average price of $0.67. Upon completion of the transaction, the Chief R&D Officer now directly owns 305,892 shares in the company, valued at $9.08 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 19 ’25, Chief Legal Officer Wilson Mark Andrew sold 9,996 shares of the business’s stock. A total of $6,697 was realized by selling the stock at an average price of $0.67. This leaves the insider owning 314,296 shares of the company worth $9.33 million. A total of 3.59% of the company’s stock is owned by insiders.
During the past 12 months, Nektar Therapeutics has had a low of $6.48 and a high of $37.38. As of last week, the company has a debt-to-equity ratio of 13.59, a current ratio of 3.24, and a quick ratio of 3.24. The fifty day moving average price for NKTR is $11.2026 and a two-hundred day moving average price translates $14.27265 for the stock.
The latest earnings results from Nektar Therapeutics (NASDAQ: NKTR) was released for 2025-03-31. The net profit margin was -152.49% and return on equity was -189.46% for NKTR. The company reported revenue of $10.46 million for the quarter, compared to $21.64 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -51.66 percent.
